All In Biotech

Drug Trial Radar · NCT06363383

A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants

A Double-blind Placebo-controlled Phase 1 Study to Evaluate the Safety and Efficacy of MB-001 in Single and Multiple Ascending Doses in Healthy Human Participants

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

May 9, 2024

Primary completion

Jul 4, 2025

Study completion Jul 4, 2025

Sponsor

Lead sponsor
Mage BiologicsIndustry
Sponsor type
Industry
Collaborators
Alimentiv Inc.
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the oral biologic MB-001 is safe in healthy volunteers. The main questions it aims to answer are: Is the drug safe when administered orally at increasing doses? Researchers will compare the drug with placebo to see if there are more side effects in those receiving the drug. Participants will receive a single or five daily doses of the drug or placebo and will be asked to stay in the clinic for five days following the last dose.

Conditions

  • Ulcerative Colitis

Interventions

  • MB-001Biological

    Oral, delayed release formulation of a biologic drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: up to day 33 post dosing
  2. Clinically significant changes from baseline in vital signsTime frame: up to day 33 post dosing
  3. Clinically significant changes from baseline in physical examination findingsTime frame: up to day 33 post dosing
  4. Clinically significant changes from baseline in clinical laboratory assessmentsTime frame: up to day 33 post dosing
  5. Clinically significant changes from baseline in ECG parametersTime frame: up to day 33 post dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.